| Page 1908 | Kisaco Research
 

Fernanda Hoe

R&D Leader Brazil Ops, Global Cattle Product Development
Elanco
  • Veterinary Medicine degree from Unesp - Botucatu, Brazil
  • Master in Science from the University of Wisconsin, USA
  • MBA from FGV, Brazil.
  • More than 15 years of experience in the Animal Health Industry. Experience in technical, sales, marketing with focus on customer insights, product positioning and launching. Since 2016 leading the R&D team in Brazil.

Fernanda Hoe

R&D Leader Brazil Ops, Global Cattle Product Development
Elanco

Fernanda Hoe

R&D Leader Brazil Ops, Global Cattle Product Development
Elanco
  • Veterinary Medicine degree from Unesp - Botucatu, Brazil
  • Master in Science from the University of Wisconsin, USA
  • MBA from FGV, Brazil.
  • More than 15 years of experience in the Animal Health Industry. Experience in technical, sales, marketing with focus on customer insights, product positioning and launching. Since 2016 leading the R&D team in Brazil.
EXCLUSIVE Skincare Report from Euromonitor
 

Dr Jordan Kerns

Principal Investigator, R&D Lead
Emulate Inc

Dr Jordan Kerns

Principal Investigator, R&D Lead
Emulate Inc

Dr Jordan Kerns

Principal Investigator, R&D Lead
Emulate Inc
 

Jack Oswald

CEO & co-founder
ISOthrive

Jack Oswald

CEO & co-founder
ISOthrive

Jack Oswald

CEO & co-founder
ISOthrive
 

Reza Zadeh

Founder & CEO
Matroid

Reza Bosagh Zadeh is Founder CEO at Matroid and an Adjunct Professor at Stanford University. His work focuses on Machine Learning, Distributed Computing, and Discrete Applied Mathematics. Reza received his PhD in Computational Mathematics from Stanford under the supervision of Gunnar Carlsson. His awards include a KDD Best Paper Award and the Gene Golub Outstanding Thesis Award. He has served on the Technical Advisory Boards of Microsoft and Databricks.

Reza Zadeh

Founder & CEO
Matroid

Reza Zadeh

Founder & CEO
Matroid

Reza Bosagh Zadeh is Founder CEO at Matroid and an Adjunct Professor at Stanford University. His work focuses on Machine Learning, Distributed Computing, and Discrete Applied Mathematics. Reza received his PhD in Computational Mathematics from Stanford under the supervision of Gunnar Carlsson. His awards include a KDD Best Paper Award and the Gene Golub Outstanding Thesis Award. He has served on the Technical Advisory Boards of Microsoft and Databricks. As part of his research, Reza built the Machine Learning Algorithms behind Twitter's who-to-follow system, the first product to use Machine Learning at Twitter. Through Apache Spark, Reza's work has been incorporated into industrial and academic cluster computing environments. In addition to research, Reza designed and teaches two PhD-level classes at Stanford: Distributed Algorithms and Optimization (CME 323), and Discrete Mathematics and Algorithms (CME 305).

 

Dr Luis Gosalbez

Director of Business Development
OptiBiotix Ltd

Luis is the Director of Business Development at OptiBiotix Health in the UK. Previously, he held different positions in the biotechnology industry and in pharmaceutical consulting in Spain and Germany. His scientific career was developed between Universidad Complutense de Madrid, Centro de Biología Molecular Severo Ochoa-CSIC (both in Spain) and the Korea Advanced Institute of Science and Technology (KAIST, South Korea). His research was always focused on microbiology, the human microbiome and on the development of antimicrobials and antivirals.

Dr Luis Gosalbez

Director of Business Development
OptiBiotix Ltd

Dr Luis Gosalbez

Director of Business Development
OptiBiotix Ltd

Luis is the Director of Business Development at OptiBiotix Health in the UK. Previously, he held different positions in the biotechnology industry and in pharmaceutical consulting in Spain and Germany. His scientific career was developed between Universidad Complutense de Madrid, Centro de Biología Molecular Severo Ochoa-CSIC (both in Spain) and the Korea Advanced Institute of Science and Technology (KAIST, South Korea). His research was always focused on microbiology, the human microbiome and on the development of antimicrobials and antivirals. He received his BSc and MSc in Biotechnology from Universidad Complutense de Madrid, his PhD in Life Sciences from the Catholic University of San Antonio (Spain) and a Master’s in Bioscience Enterprise from the University of Cambridge in the UK.

 

Dr Soren Krogsgaard Thomsen

CEO
BioMe Oxford

Dr Soren Krogsgaard Thomsen is co-founder and CEO of the UK-based start-up company BioMe Oxford. Trained in medical genetics at the Universities of Oxford and Cambridge, Soren has a background in both academic and industrial life sciences research. His publication record spans work on the genetics of complex diseases and academic entrepreneurship. Since co-founding BioMe Oxford, he has successfully led the company to raising pre-seed investment, winning a number of international business competitions along the way (incl. Imagine IF and Idea Idol).

Dr Soren Krogsgaard Thomsen

CEO
BioMe Oxford

Dr Soren Krogsgaard Thomsen

CEO
BioMe Oxford

Dr Soren Krogsgaard Thomsen is co-founder and CEO of the UK-based start-up company BioMe Oxford. Trained in medical genetics at the Universities of Oxford and Cambridge, Soren has a background in both academic and industrial life sciences research. His publication record spans work on the genetics of complex diseases and academic entrepreneurship. Since co-founding BioMe Oxford, he has successfully led the company to raising pre-seed investment, winning a number of international business competitions along the way (incl. Imagine IF and Idea Idol). Soren dreams of enabling a revolution in precision medicine through population-wide studies of our second genome within. 

 

Evelina Vågesjö, PhD MBA

CEO
Ilya Pharma

Co-founder of and developed the concept during PhD 2011-2016, is now CEO and heading the drug and business development in Ilya Pharma. Also BSc in Management Accounting and finished an MBA 2018. Raised >4.3 M€ in grant funding to the project, lead the first private share issue in 2017 and designed stock option programs for key employees.  

Evelina Vågesjö, PhD MBA

CEO
Ilya Pharma

Evelina Vågesjö, PhD MBA

CEO
Ilya Pharma

Co-founder of and developed the concept during PhD 2011-2016, is now CEO and heading the drug and business development in Ilya Pharma. Also BSc in Management Accounting and finished an MBA 2018. Raised >4.3 M€ in grant funding to the project, lead the first private share issue in 2017 and designed stock option programs for key employees.  

 

Gregory McKenzie, Ph.D.

Vice President of Research and CSO
ConsortiaTX

Gregory McKenzie, Ph.D., Vice President and Chief Scientific Officer, has over ten years of experience developing microbial-based products and leading discovery and development teams. Greg was formerly Senior Principal Scientist at Seres Therapeutics where he was a key senior member of the teams that brought the live biotherapeutics SER-109, SER-262, and SER-287 from discovery through proof-of-concept in animals to clinical stage programs. 

Gregory McKenzie, Ph.D.

Vice President of Research and CSO
ConsortiaTX

Gregory McKenzie, Ph.D.

Vice President of Research and CSO
ConsortiaTX

Gregory McKenzie, Ph.D., Vice President and Chief Scientific Officer, has over ten years of experience developing microbial-based products and leading discovery and development teams. Greg was formerly Senior Principal Scientist at Seres Therapeutics where he was a key senior member of the teams that brought the live biotherapeutics SER-109, SER-262, and SER-287 from discovery through proof-of-concept in animals to clinical stage programs.